Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC

NCT00354549 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

104

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: bevacizumab + erlotinib hydrochloride
DRUG: gemcitabine hydrochloride + cisplatin or carboplatin

Sponsor

Swiss Cancer Institute